0QAI.L - Adocia SA
| Previous close | 3.7750 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 781 |
| Market cap | 270,410 |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.2240 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireListing of ADOCIA Shares Suspended
LYON, France, June 01, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it has asked Euronext to suspend the listing of its shares on the Euronext Paris regulated market as of today, pending a press release.
Business WireNumber of Shares and Voting Rights of ADOCIA as of April 30th, 2023
LYON, France, May 16, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovativ
Business WireADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer
LYON, France, May 15, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the appointment of Olivier Soula as Chief Executive Officer of Adocia, by decision of the Board of Directors which met on May 11, 2023, in Paris. Olivier Soula succeeds Gérard Soula, whose term as Chairman of the B
Business WireADOCIA Announces the Release of its Universal Registration Document for the Year 2022
LYON, France, April 27, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its 2022 Universal Registration Document with the "Autorité des marchés financiers" (AMF - the French financial markets regulator) on April 26, 2023.
Business WireADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities
LYON, France, April 25, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial results for 2023 and provides an update on its activities.
Business WireADOCIA Announces Its Annual Shareholders’ Meeting to Be Held on May 11, 2023 in Paris
LYON, France, April 20, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting ("AGM") on May 11, 2023, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.
Business WireNumber of Shares and Voting Rights of ADOCIA as of March 31st, 2023
LYON, France, April 13, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat
Business WireNumber of Shares and Voting Rights of ADOCIA as of February 28th, 2023
LYON, France, March 17, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat
Business WireADOCIA Announces Its Annual Results for 2022 and Provides Corporate and Financial Update
LYON, France, March 15, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its annual financial results as of December 31, 2022. The consolidated financial statements were approved by the board of directors on March 14, 2023 and the audit of the accounts is being finalized.
Business WireNumber of Shares and Voting Rights of ADOCIA as of January 31st, 2023
LYON, France, February 15, 2023--Regulatory News: ADOCIA (Paris:ADOC):
Business WireAdocia Publishes Its Letter to Shareholders
LYON, France, January 30, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the January 2023 Letter to Shareholders.
Business WireADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
LYON, France, January 23, 2023--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31st, 2022:
Business WireNumber of Shares and Voting Rights of ADOCIA as of December 31st, 2022
LYON, France, January 16, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares as well as its voting rights as of December 31st, 2022.
Business WireADOCIA Announces its Financial Calendar for 2023
LYON, France, January 12, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its financial calendar for 2023.
Business WireADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao
LYON, France, December 29, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today new positive results for BioChaperone® Lispro insulin (named THDB0206 in China) with partner Tonghua Dongbao.
Business WireADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023
LYON, France, December 21, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its participation to the following investors events:
Business WireNumber of shares and voting rights of ADOCIA as of November 30th, 2022
LYON, France, December 15, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno
Business WireAdocia Strengthens Its Cash Position with EUR 6 Million Through the Issuance of Convertible Bonds Subscribed by European Investors in Order to Accelerate the Development of Key Products
LYON, France, December 01, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today the completion of a EUR 6 million financing operation.
Business WireNumber of Shares and Voting Rights of ADOCIA as of October 31st, 2022
LYON, France, November 16, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno
Business WireADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
LYON, France, October 25, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates.
Business WireNumber of Shares and Voting Rights of ADOCIA as of September 30th, 2022
LYON, France, October 13, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innov
Business WireADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
LYON, France, October 06, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005658/en/
Business WireADOCIA: Upcoming Investor Meetings
LYON, France, October 03, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will attend the following investor events:
Business WireADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
LYON, France, September 19, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its financial results for the six months ended June 30th, 2022.
Business WireAdocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th
LYON, France, September 15, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will release its first-half 2022 results on September 19th, 2022, post-market close.